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Summary: Twenty two patients with exacerbation of inflammatory bowel disease (19 with Crohn's disease, 3
with ulcerative colitis) and thrombocytosis were tested for possible activation of the coagulation and platelet
system.
Fifteen patients had abnormal platelet function i. e. unphysiologically high sensitivity in vitro towards ADP
2 μηιοΐ/ΐ aggregation induction. In 81.8% of the patients we found enhanced fibrinogen concentrations. In
22.7% of the patients thrombin-antithrombin III values exceeded the upper limit of the reference range, and
in 68.2% of the patients the D-Dimer concentration exceeded the upper reference limit as a result of reactive
fibrinolysis. The altered platelet count and function, and the increased levels of fibrinogen and thrombin-
antithrombin III with reactive fibrinolysis activation indicate the presence of prethrombotic factors in patients
with exacerbation of inflammatory bowel disease. The presence of enhanced fibrinolysis in these patients
might have consequences for the therapeutic treatment.
Introduction . .also reports on the occurrence of thrombocytosis in
As we know from the literature (1 — 3) thromboem- the exacerbation phase of inflammatory bowel dis-
bolism is an accepted complication of inflammatory ease. Until the present work, however, no data were
bowel disease. In the acute phase, F VIII, F II, fibri- available on the functional state of platelets in the
nogen, plasminogen, prekallikrein and high molecular acute phase of inflammatory bowel disease. We there-
weight kallikrein are enhanced, which could account fore investigated the in vitro aggregation activity of
for thromboembolic complications (4 — 7). No evi- the thrombocytes. For the investigation of the state
dence has been reported, however, for a prethrom- of the coagulation system we determined fibrinogen,
botic state in the stable phase of chronic inflammatory the fibrin monomer concentration and the thrombin-
bowel disease (8). Recent research on the changes in antithrombin III complex. For the investigation of
parameters of the fibrinolysis system in the peripheral fibrinolysis we chose the recently developed ELISA-
blood of patients with inflammatory bowel disease assay for the D-Dimer.
has shed some light on the nature and magnitude of
the disturbances of fibrinolysis and their relationship ^M . _ , m m . ,
/ηλ , - , . , ' - u . Materials and Methods(9) to the development of deep venous thrombosis.
There is evidence for a decrease in tissue plasminogen Patients
activator as well as an increase in plasminogen acti- Plasma samples were collected from 22 patients (16 females, 6
vator inhibitor, both effects being possible explana- males' tab· 1> with histologically proven intestinal bowel dis-
c Λ Λ - Λ Γ Λ ι ι ι · ι · ease, who visited the outpatient clinic for gastroenterology andtions for the known risk of thromboembolic compli- presented themselves for acute exacerbation of the disease. The
cations in these patients (9, 10). Moreover, there are patient group consisted of 19 patients with Crohrfs disease and
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3 patients with ulcerative colitis. The activity index of van Hees
(11) ranged from 210 — 313. The use of medication was ex-
cluded. All the female patients were using oral contraceptive
drugs. The main inclusion criterium from the laboratory point
of view was the presence of a thrombocytosis. A reference
group consisted of subjectively healthy individuals from the
hospital and laboratory staff.
Samples
For the platelet count, venous blood was collected in plastic
vials containing 1.6 g/1 EDTA-K2 (Sarstedt, Numbrecht, FRG).
Samples were kept between 30 min and 4 hours at room
temperature until analysis.
Coagulation parameters were determined in titrated plasma,
prepared by centrifugation of nine volumes freshly drawn blood
with one volume trisodium titrate (0.11 mol/1) for 10 min
(1600g) at 25 °C. The plasma was stored at -70 °C in plastic
tubes and thawed with tap water for 5 min before serial analysis.
The platelet aggregation test was performed on platelet rich
plasma, which was prepared by immediate centrifugation of
citrated blood (prepared as described above) at 200 g for 10
minutes at room temperature. After gentle aspiration of the
platelet-rich plasma, using a plastic pipette, the remaining blood
was centrifuged at 2000 # for 10 min at room temperature; the
resulting platelet-poor plasma was aspirated and subsequently
centrifuged at 10 000 g at 4 °C for 10 min to obtain platelet-
free plasma. Platelet-rich plasma and platelet-free plasma were
used for standardization of the end concentration of the platelet
count in the test. The collagen-induced aggregation was per-
formed at a thrombocyte concentration of 400 χ 109/1, whereas
the other induced aggregations were performed at a platelet
concentration of 200 χ 109/1· The spontaneous (i.e. induced
by stirring alone) aggregation was carried out in platelet-rich
plasma.
Methods
Platelets were counted with a Sysmex E-4000 (Kobe, Japan)
cell counter. Platelet aggregation was measured by a turbidi-
metric method using a Daiichi dual channel aggregation device.
The test concentrations of the different inducing agents are
quoted in the results. Fibrinogen was determined by the clotting
assay of Clauss. The FM test is a semi-quantitative test from
the Boehringer Mannheim Corp (FRG), using fibrinogen-
coated erythrocytes to detect circulating fibrin monomers in
plasma (detection level 10 mg/1). Thrombin-antithrombin III
was determined with an ELISA test kit (Behring Corporation,
Marburg, FRG). D-Dimer was assayed in plasma with an
ELISA method (Boehringer Mannheim. FRG).
Results
Values for the coagulation and fibrinolysis parameters
are presented in table 2. Close agreement between the
mean and median value was observed only in the case
of fibrinogen (5.6 and 5.8 g/1 respectively). For the
platelets, thrombin-antithrombin HI and D-Dimer the
mean values are higher than the median values (plate-
lets 575/548 χ 109/1, thrombin-antithrombin III 3.4/
2.0 μ§/1, D-Dimer 1101/630 μg/l). The range of the
values is relatively large for all parameters; in partic-
ular, the maximal D-Dimer value is 70 times higher
than the minimal value. The range for the platelets
was 400-997 χ 109/1, for fibrinogen 3.0-9.0 g/1, for
thrombin-antithrombin III 1.0 — 10.8 μg/l, and for D-
Dimer 100-7000 μ§/1.
Table 3 shows the percentages of values exceeding the
upper limits of the respective reference ranges, i. e.
fibrinogen 81.2%, the FM test 4.5%, thrombin-anti-
thrombin III concentration 22.7% and D-Dimer con-
centration 68.2%.
Table 4 compares the mean values of parameters for
the patients and the reference group. On the 95%
level the patient and reference values for fibrinogen
Tab. 2. Basic characteristics of the parameters investigated
Parameter Mean Minimum Median
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and D-Dimer were significantly different, whereas the
thrombin-antithrombin III concentrations were not.
In table 5 the results are classified according to sex.
The platelet counts were lower in males than in fe-
males (531/592 χ 109/1), as were the fibrinogen con-
centrations (4.3/6.1 g/1); for the other parameters the
relationship between males and females was reversed:
thrombin-antithrombin III 5.7 vs. 2.6 μ§/1, D-Dimer
2103 vs. 699 μg/l, and ADP 2 μηιοΐ/l aggregation 81.7
vs. 76.8%.
In the case of the platelets, fibrinogen, thrombin-
antithrombin III and D-Dimers, the sex differences
were statistically significant. Table 6 shows the com-
parison of values for male patients and for female
patients with those for the reference group. Highly
significant differences were found between the mean
values of parameters from male or female patients
and those of the reference group, with the exception
of the thrombin-antithrombin III levels in female pa-
tients.







































































































































































AA = aggregation absent NR = non reversible R = reversible
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Tab. 8. Comparison of the ADP 2 μιηοΐ/ΐ aggregation of the control and the patient group
Control group of healthy individuals
Patient group without treatment in phase
of exacerbation
ADP aggregation (2 μηιοΐ/l)
Reversible (R) Non
Α ΟΤΛ η Amax tJi-s n •'••max
(x in %) (%) (x in
30 11 49









Table 7 summarizes the results and the criteria for
normality of the different aggregation tests carried
out in this study. We found no abnormality for the
collagen, ristocetin, epinephrine or ADP 10 μηιοΐ/ΐ
platelet aggregation (0/22). One patient however pre-
sented with spontaneous aggregation, three out of
fifteen with 0.2 μηιοΐ/ΐ ADP aggregation and fifteen
of the twenty two patients with increased 2 μιηοΐ/ΐ
ADP aggregation. In table 8 we can see that the
maximal amplitude (Amax) of the 2 μτηοΙ/1 ADP ag-
gregation of the normal patient group with an Amax
of 35% hardly differs from the Amax of the control
group of healthy individuals (Amax = 30%). The dif-
ference however between the abnormal patient group
(Amax = 77.5%) and the normal patient group was
significant (p < 0.0001).
Discussion
This study was designed to investigate the basis of
the thrombocytosis in patients with Crohn's disease
and colitis ulcerosa, which is known to occur in pa-
tients with exacerbation of the disease (1, 12, 13).
From the results of this study it seems clear that the
degree of thrombocytosis is greater for females than
for males, a fact that is consistent with earlier reports
(14) of higher platelet counts for females in a reference
population. The question arises as to the degree of
thrombocytosis that can be considered as a prethrom-
botic factor. For this purpose we investigated platelet
aggregation after induction with different stimuli. One
patient showed spontaneous aggregation, three pa-
tients showed aggregation with 0.2 μηιοΐ/ΐ ADP, and
fifteen patients showed enhanced aggregation with
2 μηιοΐ/l ADP. Taking account of the need for care
in the handling and interpretation of aggregation
tests, we can conclude that the platelets of 15/22
patients showed an unphysiologically strong in vitro
reaction in the ADP 2 μηιοΐ/ΐ aggregation induction
test, which can be considered as representing a preth-
rombotic state. This is in agreement with the obser-
vations of Lake et al. (4), who reported increased
platelet counts associated with abnormal platelet
function in patients with bowel disease.
The platelet aggregation effect was of the same mag-
nitude in males and females. This was not the case
for fibrinogen, which showed a significant difference
between males and females, and a significant increase
in comparison with the reference group. Lee et al. (7)
reported similar changes in fibrinogen in chronic ul-
cerative colitis. It is conceivable that high levels of
fibrinogen may increase the risk of thrombus forma-
tion. Moreover, we know that elevation of fibrinogen
increases blood viscosity, which may in turn further
enhance the risk of thrombus formation.
In summary, it seems that, in our patient group,
fibrinogen can be considered as a risk factor for the
development of thrombosis, and to a greater degree
in women than in men. In 22.7% of the patients, the
increased thrombin-antithrombin III concentrations
suggest the possibility of clotting activation, although
the difference between the mean of the reference and
the patient group is not significant on the 95% level.
When the thrombin-antithrombin HI results were
classified according to sex, the mean for males, but
not that for females, showed a significant difference.
Ghosh et al. (15) described patients with inflammatory
bowel disease, decreased antithrombin III and a his-
tory of thrombosis, and speculated that their results
were due to an increased consumption of antithrom-
bin III. It can be concluded that coagulation activa-
tion occurs, at least in the male patients. This was
clearly established by the results of the D-Dimer anal-
ysis. Both the fact that 68.2% of the overall results
exceed the upper reference limit and the fact that the
overall mean of the D-Dimer determinations was sig-
nificantly enhanced in the patient group in relation
to the reference group can be taken as evidence for
the presence of a reactive fibrinolysis after preceeding
coagulation in these patients. This is also suggested
by the recent findings of Wakefieldti al., who reported
that Crohn's disease is mediated by multifocal gas-
trointestinal infarction (19). This is important for
understanding the pathogenesis of Crohn's disease and
its common clinical features. The strongest fibrinolysis
effect was again found in the male patients, which is
in full agreement with the previously mentioned
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thrombin-antithrombin III results for males and fe-
males. For the rest, it seems inconceivable at first
sight, that the degree of fibrinolysis would be some-
what higher than expected from the thrombin-anti-
thrombin III results. An acceptable explanation, how-
ever, could be that all the reactions caused by throm-
bin generation will ultimately result in the production
of D-Dimers.
Increased fibrinolytic activity was first described by
Kwaan et al. (16, 17) in patients with active colitis,
and Kondo et al. (18) later reported the same results.
These investigators suggested some connection be-
tween hyperfibrinolysis and anal blood loss, and re-
ported clinical improvement and reduction of blood
loss after antifibrinolytic therapy.
In summary, our study suggests the presence of pre-
thrombotic factors in the acute phase of inflammatory
bowel disease, which might contribute to an increased
risk of thrombosis, as also confirmed by de Jong et
al. (9). The activation of the fibrinolysis system in the
acute phase of inflammatory bowel disease, as shown
indirectly in this study by measurement of the D-
Dimers, must be the result of increased plaminogen
transformation. Plasmin is known to have — in ad-
dition to its main fibrinolytic function — the ability
to activate collagenases, which in excess could ad-
versely affect wound healing, a process undoubtedly
needed in these patients. Thus, it may be worth rein-
vestigating and reconsidering the treatment of these
patients with antifibrinolytic agents.
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